Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 63629-1990

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 63629-1990). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure diagram of Duloxetine Hydrochloride, showing the arrangement of atoms including sulfur, oxygen, nitrogen, and aromatic rings typical for the molecule.*

FDA Label Image

Figure 1 (Duloxetine 02)

A survival curve chart showing the proportion of patients with relapse over time in days from randomization. Two treatment groups are compared: placebo (dashed line) and duloxetine delayed-release capsules (solid line). The graph indicates relapse rates are higher in the placebo group across the observation period up to 200 days.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line graph comparing the proportion of patients with relapse over time in days for Duloxetine delayed-release capsules versus placebo. The x-axis represents time from randomization to relapse (days), and the y-axis shows the proportion of patients with relapse, ranging from 0 to 1. The graph shows lower relapse proportions for Duloxetine delayed-release capsules compared to placebo over the study period.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups labeled DUL 60mg BID, DUL 60mg QD, DUL 20mg QD, and Placebo, showing patient response rates across various pain improvement percentages.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: DUL 60mg BID, DUL 60mg QD, and Placebo, showing higher improvement percentages for both duloxetine dosing regimens compared to placebo across increasing levels of pain improvement.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo groups. The graph compares pain improvement distributions among these treatment groups over a range of pain improvement percentages from 0% to 100%.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo, with data points displayed along a horizontal axis representing pain improvement percentages ranging from greater than 0 to 100.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between placebo and Duloxetine (60/120 mg once daily). The x-axis shows percent improvement in pain from 0 to 100, and the y-axis shows percentage of patients improved from 0% to 100%. Two lines represent placebo and Duloxetine treatment groups.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two lines represent 'Placebo' and 'DUL 60 mg once daily,' showing comparative trends of patient improvement across different pain improvement percentages.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares two groups: placebo (marked with x symbols) and DULO 60/120 mg once daily (marked with black diamonds). The graph shows higher patient improvement percentages for DULO at various pain improvement thresholds.*

FDA Label Image

Label (Lbl636291990)

Label for Duloxetine Delayed-Release Capsules, USP 20 mg by Bryant Ranch Prepack. The label features the product name, strength (20 mg), and container count of 90 capsules. It includes storage instructions, safety warnings, and a barcode. The label also displays the NDC number 63629-1990-1 and the BRP Pharmaceuticals logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.